12月4日晚间，指南针发布公告称，根据麦高证券经营发展需要，公司拟对麦高证券以自有资金增资1亿 元。 据悉，麦高证券为指南针的全资子公司，在业界有"小东财"之称。此前，指南针拟定增募资30亿元，将全部用 于增资麦高证券，但今年10月底这笔定增终止了。 指南针向麦高证券增资1亿元 指南针于2025年12月4日召开第十四届董事会第十二次会议，审议通过了《关于向全资子公司麦高证券有限责 任公司增资的议案》，董事会同意公司向全资子公司麦高证券增资，并同意授权公司经营管理层具体决定和办 理上述增资相关事项。 早在2022年5月，指南针就发布了《关于公司2022年度向特定对象发行A股股票方案的议案》。根据议案，指 南针本次募集资金总额不超过30亿元，资金将全部用于增资麦高证券。 指南针表示，增资有助于麦高证券彻底摆脱历史经营困境。麦高证券发展停滞多年，各项业务亟待夯实基础， 而重整后的麦高证券资本实力依然薄弱，由资本实力直接决定的风险抵御能力仍需加强。本次募集资金有助于 根据麦高证券经营发展需要，公司拟对麦高证券以自有资金增资1亿元。本次增资完成后，麦高证券的注册资 本将由14 亿元变更为15亿元，麦高证券仍为公司全资子 ...

Core Viewpoint - The company, Guiding Compass, announced a capital increase of 100 million yuan to its wholly-owned subsidiary, Mai Gao Securities, following the failure of a previous 2.9 billion yuan fundraising plan [2][5]. Group 1: Capital Increase - Guiding Compass plans to increase the registered capital of Mai Gao Securities from 1.4 billion yuan to 1.5 billion yuan [5]. - The capital increase aims to better meet the funding needs for the business development of Mai Gao Securities, contributing to stable business progress and aligning with the company's long-term planning and core interests [5]. Group 2: Financial Impact - The funding for the capital increase will come from the company's own funds and is not expected to significantly impact the current financial status or operating results of Guiding Compass [5]. - The company also announced a plan to use up to 300 million yuan of idle funds to purchase bonds, aiming to improve capital efficiency and increase shareholder returns [5]. Group 3: Background of Mai Gao Securities - Mai Gao Securities, formerly known as Wangxin Securities, was acquired by Guiding Compass in 2022 after undergoing bankruptcy reorganization [5]. - The company had previously proposed a fundraising plan to raise up to 2.9 billion yuan, which was ultimately terminated on October 31 due to various internal and external factors [5]. Group 4: Recent Performance - Mai Gao Securities has begun to recover from previous years of losses, reporting a revenue of 324 million yuan and a net profit of 70.36 million yuan in the first half of 2025 [6]. - For the first three quarters of 2025, the company achieved a net income from fees and commissions of 366 million yuan, a year-on-year increase of 171.07%, and net interest income of 70.84 million yuan, up 54.46% [6].

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 来源：中国基金报 【导读】指南针向全资子公司麦高证券增资1亿元，此前29亿元定增折戟 中国基金报记者 晨曦 麦高证券，增资新方案来了！ 12月4日晚间，指南针发布公告称，根据麦高证券经营发展需要，公司拟对麦高证券以自有资金增资1亿 元。 麦高证券为指南针的全资子公司。此次增资完成后，麦高证券的注册资本将由14亿元变更为15亿元。 对此，指南针表示，本次增资是为了更好地满足麦高证券业务发展的资金需要，有助于麦高证券业务的 稳定推进，符合公司长远规划和核心利益，为公司未来发展打下坚实基础。此次增资的资金来源为公司 自有资金，不会对公司当前财务状况和经营成果产生重大影响，不存在损害公司和全体股东利益的情 形。 同日，指南针还发布公告称，其董事会同意公司使用额度不超过3亿元的闲置自有资金购买债券。指南 针称，投资目的是提高公司资金使用效率、增加股东回报，合理利用闲置资金。 麦高证券由原网信证券更名而来，经历破产重整后，于2022年获指南针收购，成为其全资子公司。同 年，指南针抛出定增计划，募集资金在扣除费用后全部用于增资麦高证券。在2025年5 ...

Core Viewpoint - The company, Guiding Compass, is increasing its wholly-owned subsidiary, Maigao Securities, by 100 million yuan to support its business development needs after a failed 2.9 billion yuan fundraising attempt [2][5][6]. Group 1: Capital Increase - Guiding Compass announced a capital increase of 100 million yuan for Maigao Securities, raising its registered capital from 1.4 billion yuan to 1.5 billion yuan [5]. - The capital increase aims to better meet the funding needs of Maigao Securities and is aligned with the company's long-term planning and core interests [5][6]. Group 2: Previous Fundraising Attempt - The previous fundraising plan, which aimed to raise up to 2.9 billion yuan, was terminated after three years due to various internal and external factors [6]. - The decision to terminate the fundraising was made after careful analysis and consideration of the company's strategic goals [6]. Group 3: Financial Performance of Maigao Securities - Maigao Securities has begun to recover from previous years of losses, reporting a revenue of 324 million yuan and a net profit of 70.36 million yuan in the first half of 2025 [6]. - For the first three quarters of 2025, Maigao Securities achieved a net income from fees and commissions of 366 million yuan, a year-on-year increase of 171.07% [6]. - The net interest income for the same period was 70.84 million yuan, reflecting a growth of 54.46% year-on-year [6].

Group 1 - China Pacific Insurance has received approval from the financial regulatory authority for Wang Yuhua to serve as a director [1] - Shanghai Bank announced that the regulatory authority has approved Chen Lei's qualification as vice president [2] - Shanghai HuGong has decided to terminate the "Aerospace Equipment Manufacturing Base" fundraising project due to significant changes in project feasibility [3] Group 2 - Dongwang Times plans to reduce its stake by up to 1.20% through share sales [4] - Zhinancun intends to increase its capital by 100 million yuan in its wholly-owned subsidiary, Maigao Securities [5] - Jinxinnong reported a sales revenue of 115 million yuan from pig sales in November [6] Group 3 - Tiantan Biological has completed the Phase III clinical trial of its human prothrombin complex, showing good efficacy and safety for hemophilia B patients [7] - Beijete's subsidiary has signed a framework agreement for equity acquisition to gain control of Yunnan Wenye Nonferrous Metals [8] - Zhongsheng Pharmaceutical's RAY1225 injection has received approval for a new clinical trial indication for treating metabolic-associated fatty liver disease [9] Group 4 - Enhua Pharmaceutical's hydrochloride sulpiride tablets have passed the consistency evaluation for generic drugs [10] - Shenkong Co. plans to invest 60 million yuan in a semiconductor industry fund [11] - Lianhuan Pharmaceutical's subsidiary has received approval for its drug to pass the consistency evaluation for generic drugs [12] Group 5 - Dazhong Transportation has received approval to issue debt financing tools totaling 4.5 billion yuan [13] - Jintian Titanium Industry plans to invest 50 million yuan in an industry merger and acquisition fund [14] - Changchun Gas has committed over 1.7 billion yuan to gas facility upgrades [15] Group 6 - Laimei Pharmaceutical's innovative anti-cancer drug "Nano Carbon Iron" has received approval for clinical trials [16] - Longquan Co. has signed supply contracts worth approximately 50.76 million yuan for nuclear power components [17] - Igor plans to distribute a cash dividend of 1 yuan per 10 shares [18] Group 7 - Xingfa Group's subsidiary has signed a processing agreement for 80,000 tons of lithium iron phosphate [20] - Yunjigroup's director Wang Wanfeng has resigned for personal reasons [21] - Saiseng Pharmaceutical's application for the listing of a new drug has been accepted by the regulatory authority [22] Group 8 - Xinhua Medical has obtained registration certificates for two new medical devices [23] - Chaoying Electronics plans to invest 100 million USD in its Thai subsidiary for an AI circuit board expansion project [24] - Suzhou Planning's application to acquire 100% of Dongjin Aviation has been accepted by the Shenzhen Stock Exchange [25]

指南针12月4日公告，董事会审议通过向全资子公司麦高证券增资1亿元的议案。增资完成后，麦高证券 注册资本将增至15亿元。增资旨在满足麦高证券业务发展需求，资金来源为公司自有资金，不会对公司 财务状况产生重大影响。 ...

格隆汇12月4日丨指南针(300803.SZ)公布，第十四届董事会第十二次会议，审议通过《关于使用部分闲 置自有资金购买债券的议案》，同意公司使用额度不超过人民币3亿元的闲置自有资金购买债券（风险 等级在AA以上），有效期自本次董事会批准之日起12个月。在有效期及额度范围内可循环滚动使用。 ...

截至发稿，指南针市值为741亿元。 每经头条（nbdtoutiao）——让"铁疙瘩"从数万米高空精准"踩刹车"，中国商业航天"降本复用"只差"最 后一公里"！朱雀之后，同行排队接力 （记者 曾健辉） 每经AI快讯，指南针（SZ 300803，收盘价：121.9元）12月4日晚间发布公告称，公司第十四届第十二 次董事会会议于2025年12月4日以现场结合通讯方式召开。会议审议了《关于向全资子公司麦高证券有 限责任公司增资的议案》等文件。 2024年1至12月份，指南针的营业收入构成为：互联网金融服务占比79.22%，证券业占比20.76%，其他 业务占比0.02%。 ...

格隆汇12月4日丨指南针(300803.SZ)公布，根据麦高证券经营发展需要，公司拟对麦高证券以自有资金 增资1亿元。本次增资完成后，麦高证券的注册资本将由14亿元变更为15亿元，麦高证券仍为公司全资 子公司。 ...

指南针(300803.SZ)公告称，公司于2025年12月4日召开董事会，审议通过向全资子公司麦高证券增资1 亿元的议案。增资完成后，麦高证券注册资本将增至15亿元。增资旨在满足麦高证券业务发展需求，资 金来源为公司自有资金，不会对公司财务状况产生重大影响。 ...